Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor

European Journal of Pharmacology

Volumn 543, Issue 1-3, 2006, Pages 123-132

  Kitayama, Ken ^a   Koga, Teiichiro ^b   Inaba, Toshimori ^a   Fujioka, Tomoyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

^b Sankyo Pharma Research Institute   (United States)

Author keywords

ACAT (Acyl coenzyme A:cholesterol acyltransferase); Hypercholesterolemia; Inhibitor; Pactimibe

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; PACTIMIBE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HAMSTER; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INTESTINE ABSORPTION; LIPID ABSORPTION; LIVER; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYL-COA C-ACYLTRANSFERASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE; CHOLESTEROL; CHOLESTEROL ESTERASE; CHOLESTEROL, VLDL; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HYPERCHOLESTEROLEMIA; INDOLEACETIC ACIDS; INTESTINAL ABSORPTION; LIVER; MACACA FASCICULARIS; MALE; MESOCRICETUS; PHOSPHOLIPIDS; POSTPRANDIAL PERIOD; RATS; RATS, SPRAGUE-DAWLEY; STEROL ESTERASE; STEROL O-ACYLTRANSFERASE; TIME FACTORS; TRIGLYCERIDES;

EID: 33746198749     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.05.036     Document Type: Article

References (29)

1. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., and Veltri E.P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
2. Burgess J.W., Boucher J., Neville T.A., Rouillard P., Stamler C., Zachariah S., and Sparks D.L. Phosphatidylinositol promotes cholesterol transport and excretion. J. Lipid Res. 44 (2003) 1355-1363
3. Cannon C.P., Murphy S.A., and Braunwald E. Intensive lipid lowering with atorvastatin in coronary disease. N. Engl. J. Med. 353 (2005) 93-96 (author reply 93-96)
4. Carey M.C. Critical tables for calculating the cholesterol saturation of native bile. J. Lipid Res. 19 (1978) 945-955
5. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226 (1957) 497-509
6. Hatch F.T. Practical methods for plasma lipoprotein analysis. Adv. Lipid Res. 6 (1968) 1-68
7. Hori M., Satoh M., Furukawa K., Sakamoto Y., Hakamata H., Komohara Y., Takeya M., Sasaki Y., Miyazaki A., and Horiuchi S. Acyl-coenzyme A:cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1689-1695
8. Ioriya K., Noguchi T., Muraoka M., Fujita K., Shimizu H., and Ohashi N. Effect of SMP-500, a novel acyl-coA:cholesterol acyltransferase inhibitor, on the cholesterol esterification and its hypocholesterolemic properties. Pharmacology 65 (2002) 18-25
9. Kitayama, K., Tanimoto, T., Koga, T., Terasaka, N., Fujioka, T., Inaba, T., in press. Importance of acyl-coenzyme A:cholesterol acyltransferase1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur. J. Pharmacol. (2006 Apr 29, Epub ahead of print).
10. Krause B.R., Bousley R.F., Kieft K.A., and Stanfield R.L. Effect of the ACAT inhibitor CI-976 on plasma cholesterol concentrations and distribution in hamsters fed zero- and low-cholesterol diets. Clin. Biochem. 25 (1992) 371-377
11. Lundman P., Eriksson M., Schenck-Gustafsson K., Karpe F., and Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 96 (1997) 3266-3268
12. Ma P.T., Gil G., Sudhof T.C., Bilheimer D.W., Goldstein J.L., and Brown M.S. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 8370-8374
13. Marzetta C.A., Savoy Y.E., Freeman A.M., Long C.A., Pettini J.L., Hagar R.E., Inskeep P.B., Davis K., Stucchi A.F., Nicolosi R.J., et al. Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys. J. Lipid Res. 35 (1994) 1829-1838
14. Matsui Y., Horiuchi K., Yamamoto K., and Kanai K. Pharmacological properties of R-755, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in cholesterol-fed rats, hamsters and rabbits. Jpn. J. Pharmacol. 85 (2001) 423-433
15. Nissen S.E., Tuzcu E.M., Brewer H.B., Sipahi I., Nicholls S.J., Ganz P., Schoenhagen P., Waters D.D., Pepine C.J., Crowe T.D., Davidson M.H., Deanfield J.E., Wisniewski L.M., Hanyok J.J., Kassalow L.M., and Intravascular Atherosclerosis Treatment Evaluation (A.C.T.I.V.A.T.E.) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354 (2006) 1253-1263
16. Riddell D., Bright C.P., Burton B.J., Bush R.C., Harris N.V., Hele D., Moore U.M., Naik K., Parrott D.P., Smith C., and Williams R.J. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem. Pharmacol. 52 (1996) 1177-1186
17. Rudel L.L., Davis M., Sawyer J., Shah R., and Wallace J. Primates highly responsive to dietary cholesterol up-regulate hepatic ACAT2, and less responsive primates do not. J. Biol. Chem. 277 (2002) 31401-31406
18. Scandinavian-Simvastatin-Survival-Study-Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
19. Schnitzer-Polokoff R., Compton D., Boykow G., Davis H., and Burrier R. Effects of acyl-CoA: cholesterol O-acyltransferase inhibition on cholesterol absorption and plasma lipoprotein composition in hamsters. Comp. Biochem. Physiol., A 99 (1991) 665-670
20. Sehayek E., and Eisenberg S. The role of native apolipoprotein B-containing lipoproteins in atherosclerosis: cellular mechanisms. Curr. Opin. Lipidol. 5 (1994) 350-353
21. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., and Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333 (1995) 1301-1307
22. Shiomi M., and Ito T. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits. Metabolism 43 (1994) 559-564
23. Spady D.K., and Dietschy J.M. Dietary saturated triacylglycerols suppress hepatic low density lipoprotein receptor activity in the hamster. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4526-4530
24. Suckling K.E., Benson G.M., Bond B., Gee A., Glen A., Haynes C., and Jackson B. Cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment. Atherosclerosis 89 (1991) 183-190
25. Sugiyama Y., Odaka H., Itokawa S., Ishikawa E., Tomari Y., and Ikeda H. TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters. Atherosclerosis 118 (1995) 145-153
26. Terpstra A.H., Holmes J.C., and Nicolosi R.J. The hypocholesterolemic effect of dietary soybean protein vs. casein in hamsters fed cholesterol-free or cholesterol-enriched semipurified diets. J. Nutr. 121 (1991) 944-947
27. Turley S.D., Daggy B.P., and Dietschy J.M. Cholesterol-lowering action of psyllium mucilloid in the hamster: sites and possible mechanisms of action. Metabolism 40 (1991) 1063-1073
28. Turley S.D., Herndon M.W., and Dietschy J.M. Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J. Lipid Res. 35 (1994) 328-339
29. Willner E.L., Tow B., Buhman K.K., Wilson M., Sanan D.A., Rudel L.L., and Farese Jr. R.V. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1262-1267